http://www.unboundmedicine.com/medline/ebm/research/fludarabineUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19919649/full_citation/Fludarabine_Bortezomib_Myocet_and_rituximab_chemotherapy_in_relapsed_and_refractory_mantle_cell_lymphoma_Orciuolo E, Buda G, Pelosini M, et al. 
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 16.
Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19915635/full_citation/Fludarabine_based_reduced_intensity_conditioning_transplants_have_a_higher_incidence_of_cytomegalovirus_reactivation_compared_with_myeloablative_transplants_George B, Kerridge I, Gilroy N, et al. 
Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. [JOURNAL ARTICLE]
Bone Marrow Transplant 2009 Nov 16.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19915381/full_citation/Successful_treatment_of_T_cell_prolymphocytic_leukemia__T_PLL__with_fludarabine_monophosphate_Maeda A, Iwai K, Ishibashi T 
Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate. [Journal Article]
Rinsho Ketsueki 2009 Aug; 50(8):658-62.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19912215/full_citation/Unrelated_stem_cell_transplantation_after_reduced_intensity_conditioning_for_patients_with_multiple_myeloma_relapsing_after_autologous_transplantation_Kröger N, Shimoni A, Schilling G, et al. 
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 12.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19911856/full_citation/Current_and_emerging_treatments_for_chronic_lymphocytic_leukaemia_Robak T, Jamroziak K, Robak P 
Current and emerging treatments for chronic lymphocytic leukaemia. [Journal Article]
Drugs 2009; 69(17):2415-49.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19911397/full_citation/R_roscovitine__Seliciclib__affects_CLL_cells_more_strongly_than_combinations_of_fludarabine_or_cladribine_with_cyclophosphamide:_Inhibition_of_CDK7_sensitizes_leukemic_cells_to_caspase_dependent_apoptosis_Rogalińska M, Błoński JZ, Komina O, et al. 
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. [JOURNAL ARTICLE]
J Cell Biochem 2009 Nov 12.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19804688/full_citation/Rituximab_for_the_treatment_of_relapsed_or_refractory_stage_III_or_IV_follicular_non_Hodgkin's_lymphoma_Boland A, Bagust A, Hockenhull J, et al. 
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. [Journal Article, Research Support, Non-U.S. Gov't]
Health Technol Assess 2009 Sep.:41-8.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19900571/full_citation/Low_dose_Total_Body_Irradiation_and_Fludarabine_Conditioning_for_HLA_Class_I_Mismatched_Donor_Stem_Cell_Transplantation_and_Immunological_Recovery_in_Patients_with_Hematological_Malignancies:_A_Multi_Center_Trial_Nakamae H, Storer BE, Storb R, et al. 
Low-dose Total Body Irradiation and Fludarabine Conditioning for HLA-Class I Mismatched Donor Stem Cell Transplantation and Immunological Recovery in Patients with Hematological Malignancies: A Multi-Center Trial. [JOURNAL ARTICLE]
Biol Blood Marrow Transplant 2009 Nov 6.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19897573/full_citation/Purified_T_depleted_CD34+_peripheral_blood_and_bone_marrow_cell_transplantation_from_haploidentical_mother_to_child_with_thalassemia_Sodani P, Isgro A, Gaziev J, et al. 
Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. [JOURNAL ARTICLE]
Blood 2009 Nov 6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19896080/full_citation/A_novel_GVHD_prophylaxis_with_low_dose_alemtuzumab_in_allogeneic_sibling_or_unrelated_donor_hematopoetic_cell_transplantation:_the_feasibility_of_deescalation_Bertz H, Spyridonidis A, Wäsch R, et al. 
A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. [Journal Article]
Biol Blood Marrow Transplant 2009 Dec; 15(12):1563-70.
Abstract | Full Citation